Abstract: The present disclosure relates to compositions and methods for reducing expression of MYC gene in a cell. In some embodiments, an expression repressor comprises a targeting moiety that binds a MYC promoter, anchor sequence, or super-enhancer. In some embodiments, the expression repressor comprises an effector moiety that represses transcription or methylates DNA. Systems comprising two expression repressors are also disclosed. The compositions can be used, for example, to treat cancers such as HCC or NSCLC.

Abstract: An injection molding apparatus comprises a support base and a mold carrier removably mounted to the support base. The mold carrier includes a mounting plate with attachment features for engaging the support base. A mold with two mold plates is slidably mounted to the mounting 5 plate. A clamp is operable to move the plates between open and closed positions. In the closed position, the plates abut one another. In the open position, the plates are spaced apart for removing molded articles.

Abstract: At a managed control plane service, constituent services and operational requirements of an application are identified. In response to an end-user request directed to the application, contents of an inter-service request are generated at a resource selected by the managed control plane service for a first constituent service, and a response to the message is generated at another resource selected for a second constituent service. Tasks to be performed for the operational requirements are initiated by the managed control plane service.

Abstract: A process for micro-tissue encapsulation of cells includes coating a tissue scaffold stamp with an extracellular matrix compound. The process includes depositing the tissue scaffold stamp onto a thermoresponsive substrate and seeding the tissue scaffold stamp with a cell culture. A cell culture forms a cell patch that is attached to the extracellular matrix compound. A monolayer on the tissue scaffold stamp for which borders of the monolayer maintain expressions for cell-cell junctions, wherein the cell-cell junctions of the monolayer are configured to express tension forces. The process includes removing the thermoresponsive substrate. The process includes folding the micro-tissue structure by suspending the micro-tissue in the solvent. The folded micro-tissue structure is collected from the solvent and administered to an organism.

Abstract: The present disclosure relates to site-specific disrupting agents for modulating, e.g., decreasing, expression of a target plurality of genes in a cell. In some embodiments, the target plurality of genes comprises pro-inflammatory genes, e.g., CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, and IL-8. In some embodiments, the method comprises using a first site-specific disrupting agent that targets a first anchor sequence and a second site-specific disrupting agents that disrupts a second anchor sequence.

Abstract: A system includes a jig and a processor. The jig includes a pressure wave damping element under test, and a sensor that is coupled with an aspiration line of a phacoemulsification system distally to the pressure wave damping element, the sensor configured to measure a pressure wave traveling distally in the aspiration line. The processor is coupled with the jig, the processor configured to analyze and display readings of the sensor, so as to allow a user to assess pressure wave damping performance of the pressure wave damping element.

Abstract: Systems and methods are provided for detecting the actual tip or tip type being used on a handpiece of an ophthalmic instrument. By detecting the tip type being used, the correct system settings can be used during the surgical procedure, and the surgical system may operate safely.

Abstract: Disclosed herein are system, apparatus, article of manufacture, method and/or computer program product embodiments, and/or combinations and sub-combinations thereof, for using electrical button matrix scanning techniques to detect remote control buttons pressed by users. An example embodiment operates by detecting, using an electrical matrix scanning technique, an actuated electrical switch corresponding to a remote control action for a media device. The actuated electrical switch includes a first actuated electrode coupled to a first actuated electrical line of an electrical matrix, a second actuated electrode coupled to a second actuated electrical line of the electrical matrix, and a third actuated electrode coupled to a third actuated electrical line of the electrical matrix. In response to detecting the actuated electrical switch, the example embodiment operates by triggering an execution of the remote control action corresponding to the actuated electrical switch.

Abstract: A card handling device is configured to arrange one or more cards into sets or hands. The card handling device may have a card receiving area, a card infeed mechanism for delivering cards from the receiving area to a receiver for forming the card sets or hands, and an ejector for ejecting cards to a card dispensing area. The receiving area may have a card engaging movable sidewall. The card receiver may be movable and have vertically spaced dividers which define card receiving pockets. A top of the card dispensing area is located above a top of the card receiving area.

Abstract: The present disclosure relates generally to disruption of genomic complexes associated with fusion genes via a disrupting agent comprising a targeting moiety and/or an effector, e.g., disrupting, moiety. Described herein are experiments directed at identifying target anchor sequences proximal to fusion genes, e.g., fusion oncogenes; targeting the genomic complexes, e.g., CFLs, comprising said target anchor sequences for disruption (e.g., inhibiting their formation and/or destabilizing them) using disrupting agents; and evaluating the effects of disruption on fusion gene expression and other cell (e.g., cancer cell) characteristics (e.g., growth, viability, etc.).

Abstract: The present disclosure relates generally to methods and compositions for modulating frataxin (FXN) expression, e.g., to treat Friedreich ataxia (FRDA).

Abstract: The present invention provides agents and compositions for modulating expression (e.g., enhanced or reduced expression) of a hepatocyte nuclear factor 4 alpha (HNF4a) gene by targeting an HNF4? expression control region and methods of use thereof for treating an HNF4? associated disorder, e.g., cirrhosis.

Abstract: A method and system for additive manufacturing are provided herein. The method comprises depositing a structure material, by a nozzle (810), into a support material (808) by applying to the structure material such that the structure material flows through the nozzle. The structure material comprises a polymer and a rheological modifier. Depositing of the structure material is repeated as necessary to create an object (814). The support material is at least partially removed from object. In various examples, the method comprises varying a print parameter from a first portion of the object to a second portion of the object, moving the nozzle away from a previously deposited layer of the object when repositioning for deposition of a subsequent layer of the object, or a combination thereof.

Abstract: A sample collection and processing apparatus includes a tissue processing cassette and a biopsy device. The tissue processing cassette is sized to be used in a pathology laboratory for purposes of dehydrating, embedding and sectioning. The tissue processing cassette has at least one distal opening through which tissue samples are received and has a floor with a plurality of openings. The biopsy device has a cassette holder adapted to receive the tissue processing cassette. The cassette holder has a fluid path adapted to be coupled to a vacuum source and in fluid communication with the interior of the tissue processing cassette through the openings of the floor such that vacuum from the vacuum source facilitates the transfer of the cut tissue samples into the received tissue processing cassette.

Abstract: The present invention provides agents and compositions for modulating expression (e.g., enhanced or reduced expression) of an apolipoprotein B (APOB) gene by targeting an APOB expression control region and methods of use thereof for treating an APOB associated disorder, e.g., hypercholesterolemia.

Abstract: A method of obtaining and analyzing at least one tissue sample includes forming, in a tissue container, first tracking data associated with the at least one tissue sample. Second tracking data is formed, in a transport container. The second tracking data is associated with the at least one tissue sample. The at least one tissue sample is placed in the tissue container. The first and second tracking data from the tissue container and the transport container are scanned with an electronic scanning system to ensure that the first and second tracking data are both associated with the removed tissue sample.

Abstract: A biopsy procedure may have ten or more high-level steps that a particular facility is able to perform, including radiology, transfer to pathology, grossing, processing and fixation, embedding, microtomy, H&E staining, coverslipping, slide preparation, and IHC. More than seven hundred individual risk points exist throughout the performance of each of these steps, each with varying likelihood of occurrence and severity of result. A software application provides a guided assessment that may be performed to assess a risk level for the facility. The assessment identifies approximately thirty observable characteristics of the facility, each of which may implicate one or more of the seven hundred risk points. Responses to the assessment may be used to produce a current risk metric for a facility, as well as identify a post-control risk metric for the facility, which may be achieved by implementing processes and controls to address the observable characteristics of the facility.

Abstract: The invention relates to a kit comprising at least a first composition and a second composition, each said first and second compositions comprising at least one epitope of a liver disease antigen, wherein said epitope is a CD8+T cell epitope, for use in induction of an immune response in the liver of a mammalian subject by administration of said first composition by intramuscular (i.m.), subcutaneous (s.c.), intradermal (i.d.) or aerosol route, and administration of said second composition by intravenous (i.v.) or subcutaneous (s.c.) route, characterised in that said first and second compositions are administered by different routes. The invention also relates to uses, methods and treatments.